Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer - Seidman, A D; Brufsky, A; Ansari, R H (Ann Oncol, 2011)
et al.